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https://doi.org/10.1053/j.gastro.2019.05.013BACKGROUND & AIMS: Alpha-1 antitrypsin deficiency (AATD)
is among the most common genetic disorders. Severe AATD is
caused by a homozygous mutation in the SERPINA1 gene that
encodes the Glu342Lys substitution (called the Pi*Z mutation,
Pi*ZZ genotype). Pi*ZZ carriers may develop lung and liver
diseases. Mutation-associated lung disorders have been well
studied, but less is known about the effects in liver. We
assessed the liver disease burden and associated features in
adults with this form of AATD. METHODS: We collected data
from 554 Pi*ZZ adults (403 in an exploratory cohort, 151 in a
confirmatory cohort), in 9 European countries, with AATD who
were homozygous for the Pi*Z mutation, and 234 adults without
the Pi*Z mutation (controls), all without pre-existing liver
disease. We collected data on demographic parameters, comor-
bidities, lung- and liver-related health, and blood samples for
laboratory analysis. Liver fibrosis was assessed non-invasively
via the serum tests Aspartate Aminotransferase to Platelet
Ratio Index and HepaScore and via transient elastography. Liver
steatosis was determined via transient elastography-based
controlled attenuation parameter. We performed histologic
analyses of livers from transgenic mice that overexpress the
AATD-associated Pi*Z variant. RESULTS: Serum levels of liver
enzymes were significantly higher in Pi*ZZ carriers vs controls.
Based on non-invasive tests for liver fibrosis, significant fibrosis
was suspected in 20%–36% of Pi*ZZ carriers, whereas signs of
advanced fibrosis were 9- to 20-fold more common in Pi*ZZ
carriers compared to non-carriers. Male sex; age older than 50
years; increased levels of alanine aminotransferase, aspartate
aminotransferase, or g-glutamyl transferase; and low numbers
of platelets were associated with higher liver fibrosis burden.
We did not find evidence for a relationship between lung
function and liver fibrosis. Controlled attenuation parameter
280 dB/m, suggesting severe steatosis, was detected in 39%
of Pi*ZZ carriers vs 31% of controls. Carriers of Pi*ZZ had lower
serum concentrations of triglyceride and low- and very-low-
density lipoprotein cholesterol than controls, suggesting
impaired hepatic secretion of lipid. Livers from Pi*Z-
overexpressing mice had steatosis and down-regulation of
genes involved in lipid secretion. CONCLUSIONS: In studies
of AATD adults with the Pi*ZZ mutation, and of
Pi*Z-overexpressing mice, we found evidence of liver steatosisand impaired lipid secretion. We identified factors associated
with significant liver fibrosis in patients, which could facilitate
hepatologic assessment and counseling of individuals
who carry the Pi*ZZ mutation. ClinicalTrials.gov Number
NCT02929940.Keywords: TE; ALT; Rare Liver Disease; AST.
lpha-1 antitrypsin (AAT) is the major protease in-
1Ahibitor and one of the most abundant glycoproteins
in the serum.2 AAT is primarily responsible for inhibition of
neutrophil elastase and proteinase 3. Additionally, it has
several immunomodulatory functions.3 AAT is the proto-
typic member of the serpin superfamily encoded by the
SERPINA1 gene and is mainly produced by hepatocytes.4,5
After synthesis, AAT is translocated into the endoplasmic
reticulum, where it is folded to be secreted from the hepa-
tocyte into the bloodstream.6,7 AAT variants, which are
found in up to 10% of Caucasians, mostly interfere with the
secretion process, leading to AAT accumulation in hepato-
cytes3,8 and lack of AAT in the blood.1,5 The resulting con-
dition, termed AAT deficiency (AATD), represents one of the
most common genetic disorders leading to death.9 Severe
AATD is caused mainly by the homozygous Pi*Z (Glu342-
Lys) mutation (Pi*ZZ genotype, protease inhibitor [Pi]).
Pi*ZZ carriers are highly susceptible to early-onset lung
WHAT YOU NEED TO KNOW
BACKGROUND
Alpha1-antitrypsin deficiency (AATD) can be caused by a
homozygous mutation in the SERPINA1 gene that
encodes the Glu342Lys substitution (called the Pi*Z
mutation; Pi*ZZ genotype). Pi*ZZ carriers often develop
lung and liver diseases; we assessed the liver disease
burden and features in adults with this form of AATD.
FINDINGS
Alpha-1 antitrypsin deficiency (AATD) can be caused by a
homozygous mutation in the SERPINA1 gene that
encodes the Glu342Lys substitution (called the Pi*Z
mutation). Pi*ZZ carriers often develop lung and liver
diseases; we assessed the liver disease burden and
features in adults with this form of AATD.
IMPACT
This information could facilitate hepatologic assessment
and counseling of patients who carry the Pi*ZZ mutation.
LIMITATIONS
Most Pi*ZZ carriers do not develop symptoms of AATD
and remain undetected. These findings might not apply
to this population.







Remphysema and liver disease, representing the major cau-
ses of AATD-related mortality.4,5 Since the discovery of
AATD more than 50 years ago,4,5 the Pi*ZZ-related lung
disease has been a subject of intense research. It represents
a loss-of-function phenotype, as deficiency of AAT is asso-
ciated with accelerated destruction of lung parenchyma,
leading to emphysema.4,5 This observation led to introduc-
tion of intravenous AAT augmentation as a treatment
inhibiting the accelerated lung destruction and progression
of emphysema.10,11
In contrast to Pi*ZZ-related lung disease, there is a lack
of knowledge for Pi*ZZ-related liver disease, which consti-
tutes a toxic “gain-of-function” phenotype arising from he-
patic accumulation of misfolded Pi*Z polymers.3,12 While
lung emphysema usually develops in mid-life, Pi*ZZ-related
liver disease displays a biphasic pattern12,13; children sur-
viving the critical first years of life have mostly unaltered
serum liver enzymes during adolescence.14–16 The second
peak of Pi*ZZ-related liver disease is thought to occur
around 50 years of age, when a subset of Pi*ZZ carriers
develop chronic liver disease, leading to progressive liver
fibrosis.4,5,17 Nevertheless, the natural history as well as the
prevalence of Pi*ZZ-related liver disease in adults remain
poorly characterized,18 and the current textbook knowledge
is based mainly on small studies. This lack of published data
is particularly striking because its prevalence among Cau-
casians (1:2000–40004,14) is higher than the prevalence of
other, well-characterized liver disorders (eg, autoimmune
hepatitis 1:5900–9100,19 primary sclerosing cholangitis
1:6200–8000,20 or Wilson disease 1:30,000–100,00021). For
example, a landmark study that revealed a high prevalence
of cirrhosis in Pi*ZZ subjects relied on only 16 autopsied
adults.22 Another report assessed 32 Pi*ZZ individuals from
a Swedish birth screening program14 by acoustic radiationforce impulse elastography. However, these patients were
only 37–40 years old, that is, well before the age when
clinically relevant Pi*ZZ-related liver fibrosis is expected to
occur.23 A recent study evaluated the burden of liver
fibrosis in a cohort of 94 biopsied Pi*ZZ carriers.24 Notably,
it demonstrated a fair correlation between histologic liver
fibrosis scores and non-invasive liver fibrosis assessments,
thereby setting a rationale for evaluation of large, real-life
patient cohorts.
Due to the shortage of knowledge, in particular with
regard to non-invasive assessment of liver fibrosis burden,
the current management of adult Pi*ZZ patients is based
primarily on measurement of serum liver enzymes, although
it has been described that they fail to reliably predict the
course of disease.25 Led by the a priori hypothesis that Pi*ZZ
carriers develop a liver disease more frequently than non-
carriers, and that the Pi*Z retention within the endo-
plasmic reticulum results in multiple metabolic alterations,
we performed, to our knowledge, the largest systematic
assessment of liver disease burden and laboratory param-
eters in a multinational cohort of Pi*ZZ carriers. The goal of
our study was to provide data needed for evidence-based
patient management and counseling.Methods
Study Population
A total of 554 Pi*ZZ carriers and 234 Pi*Z non-carriers
(normal AAT phenotype) have been examined (Figure 1).
Four hundred and three Pi*ZZ and 151 Pi*ZZ carriers
comprised the exploratory (Table 1 and Supplementary
Table 1) and confirmatory cohort (Supplementary Table 2),
respectively. All participants were adults of self-reported Eu-
ropean descent. Further details are given in the Supplementary
Material (Recruitment of Study Population).
Pi*ZZ carriers from Germany, Austria, Switzerland, Great
Britain, Denmark, Portugal, Spain, Belgium, and The
Netherlands were recruited in collaboration with national pa-
tient advocacy groups, physicians with a specialist interest in
AATD, as well as national AATD registries in these countries.
Therefore, most carriers had a pre-existing diagnosis of AATD,
either due to the presence of AATD-related lung disease or due
to family screenings.
Pi*Z non-carriers had been recruited from genetically un-
related spouses of patients with known AATD, as well as vol-
unteers during “liver awareness days,” that are offered yearly
by the University Hospital Aachen, Germany as a liver checkup
for the general population. In all non-carriers, the serum level
of AAT was determined and genotyping for the Pi*Z variant was
performed. Individuals with AAT serum levels 110 mg/dL or
presence of a Pi*Z variant were excluded from the study
(10 individuals were excluded).
The inclusion criteria were a valid assessment via transient
elastography (TE; FibroScan, Echosens, Paris, France) based on
published recommendations26,27 and an ability to provide
written informed consent. Main exclusion criteria were age
younger than 18 years and pregnancy. All participants have
been examined and all examinations (ie, questionnaires, clinical
examination, blood sampling, and TE) were performed on the
same day. A liver comorbidity was excluded by a
Figure 1.Overview of analyzed patients. Pi*Z is the charac-
teristic, disease-causing genetic variant of alpha-1 anti-
trypsin. Pi*ZZ is the homozygous carriage of the Pi*Z variant.
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LIVERcomprehensive workup. TE constitutes the best-established
method for non-invasive assessment of liver fibrosis via liver
stiffness measurement (LSM)26,27 and is a reliable tool to assess
steatosis via controlled attenuation parameter (CAP).28 Further
details are given in the Supplementary Material (Assessment of
Liver Disease and Ethical Statement).Assessment of Liver Disease
In all participants, the presence of a previously diagnosed
liver disease has been excluded by personal interview (ie, no
established diagnosis of chronic liver disease and no history of
liver resection or liver transplantation) and laboratory workup.
To non-invasively assess the degree of liver fibrosis, LSMs
were performed by TE (FibroScan) using the M or XL probe
according to published recommendations26 (eg, exclusion of
confounders such as non-fasting or the presence of hepatic
inflammation or cholestasis). At the same time, CAP was
assessed as a surrogate of liver steatosis. Previously recom-
mended, etiology-unspecific cutoffs for LSM and CAP were
used.26,28 For LSM, these cutoffs (7.1 kPa, suggestive of signif-
icant fibrosis and 10.0 kPa, suggestive of advanced fibrosis)
were chosen, as they imply a higher positive predictive value
compared to the lower cutoffs described in the only study
comparing LSM with histology24 (5.45 kPa for significant
fibrosis and 8.45 kPa for advanced fibrosis; both with rather
high negative predictive value, but low positive predictive
value). TE measurements at all sites had been carried out by
experienced physicians and only patients with at least 10 valid
measurements and an interquartile range 30% of median
LSM have been evaluated.
To further non-invasively assess the degree of liver fibrosis,
we used 2 serum-based liver fibrosis tests. AspartateAminotransferase (AST) to Platelet Ratio Index (APRI), an
established liver fibrosis test comprising indirect markers,29
was calculated as follows: [AST (U/L) / 40] / platelet count
(G/L). The HepaScore, a combination of direct and indirect liver
fibrosis markers,30 was determined using the following pa-
rameters: age, sex, a2-macroglobulin, hyaluronic acid, bilirubin,
and g-glutamyl transferase (GGT). We employed previously
suggested cutoffs for significant liver fibrosis (ie, F2 and higher)
and advanced liver fibrosis (ie, F3 and higher) for both APRI
and HepaScore.31–34
Pi*Z-Overexpressing Mice and Quantification of
Hepatic Steatosis
Previously characterized transgenic, 8- to 12-week-old, sex-
matched mice overexpressing the human Pi*Z variant35 and
their non-transgenic littermates were analyzed. Further details
are given in the Supplementary Material.
Statistical Analysis
Continuous variables were displayed as mean ± SD and
were compared by unpaired, 2-tailed t-tests, as well as by a
multivariate linear model to account for confounders. Cate-
gorical variables were reported as absolute (n) and relative (%)
frequencies and contingency tables were analyzed with c2
tests. Differences between groups were assessed by univariate
and forward-stepwise multiple logistic regression analyses to
calculate odds ratios (OR). ORs were given with their corre-
sponding 95% confidence intervals (CIs). Multivariable logistic
regression was used to test for independent associations.
Linear correlations between clinical variables and serum bio-
markers or elastography parameters were assessed by Pearson
or Spearman correlation coefficients, where appropriate.
Nominal P values were reported for all statistical tests. The
Bonferroni correction accounted for multiple testing. Differ-
ences were considered to be statistically significant when
P < .05. Statistical analyses were performed using SPSS, version
23 (IBM, Armonk, NY) and graphs were created with Prism
5 (GraphPad, La Jolla, CA).
Results
Clinical and Biochemical Characteristics of Pi*ZZ
Carriers
First, we assessed 403 adult Pi*ZZ carriers and 234 adult
non-carriers, both without previously known liver disease
and without clinical or laboratory signs of previously
existing liver disease (exploratory cohort; Figure 1). Both
groups had similar age, sex distribution, body mass index
values, and comparable rates of diabetes mellitus (Table 1).
Relevant alcohol consumption (>12 g/d for women and
>24 g/d for men) was infrequent in both groups (Table 1).
As expected, Pi*ZZ carriers had significantly higher Chronic
Obstructive Pulmonary Disease Assessment Test (CAT)
scores (a questionnaire measuring the health-related quality
of life) and 26% required long-term oxygen therapy (LTOT)
as an indicator of severe AATD-related lung disease
(Table 1). Interestingly, while 90% of Pi*ZZ carriers un-
derwent regular lung checkups, only 45% were subjected
to measurements of serum liver enzymes at least once a
Table 1.Characteristics of Homozygous Carriers of the alpha-1 antitrypsin Pi*Z Variant (Pi*ZZ) and Pi*Z Non-Carriers
(Exploratory Cohort)
Variable Non-carriers (n ¼ 234) Carriers (Pi*ZZ) (n ¼ 403) P value
Characteristics
Age, y 53.1 ± 14.6 54.1 ± 13.0 .39
Women 48.7 45.4 .42
BMI, kg/m2 25.1 ± 3.8 24.8 ± 4.4 .34
Mean alcohol consumption, g/d 7.9 ± 10.1 6.6 ± 10.3 .14
AAT serum level,a mg/dLb 139.7 ± 25.3 28.6 ± 16.6 <.001
Risk factors
BMI 30 kg/m2 14.9 13.0 .51
Waist circumference, cm 102.0 ± 4.6 95.0 ± 14.2 .40
Diabetes mellitus 5.6 5.0 .78
Relevant alcohol intakec 12.8 10.4 .38
Lung status
Cigarette consumption, pack-years 9.3 ± 17.8 10.0 ± 14.0 .62
CAT score (points)b 6.8 ± 6.0 16.9 ± 7.7 <.001
Long-term oxygen treatmentb 0.4 25.8 <.001
Liver status
Liver stiffness, kPab 4.6 ± 1.7 6.7 ± 5.8 <.001
Liver stiffness 7.1 kPab 6.4 23.6 <.001
Liver stiffness 10.0 kPab,d 1.3 13.6 <.001
CAP, dB/mb 246 ± 59 267 ± 57 <.001
CAP 248 dB/me 48.2 61.1 .002
CAP 280 dB/mf,g 28.4 38.7 .012
APRI, unitsb 0.27 ± 0.12 0.41 ± 0.36 <.001
APRI 0.50 unitse 5.4 19.6 <.001
APRI 1.00 unitse,h 0.5 4.5 .005
HepaScore, unitsb 0.25 ± 0.21 0.43 ± 0.32 <.001
HepaScore 0.48 unitsb 13.5 36.3 <.001
HepaScore 0.72 unitsb,i 4.1 25.6 <.001
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%). The cutoffs used for the non-invasive
liver parameters are according to etiology-unspecific recommendations from the literature: liver stiffness 7.1 kPa, APRI
0.50 units, and HepaScore 0.48 units as indicators of significant fibrosis (fibrosis stage 2) and liver stiffness 10.0 kPa,
APRI 1.00 units, and HepaScore 0.72 units as surrogates of advanced fibrosis (fibrosis stage 3).
BMI, body mass index.
aAAT serum levels of Pi*Z non-carriers and Pi*ZZ subjects, who did not receive AAT augmentation therapy, are shown. Mean
AAT serum level of all Pi*ZZ patients was 72.5 ± 52.6 mg/dL.
bP < .001 (both univariable and multivariable analysis).
cAlcohol intake >12 g/d for women and >24 g/d for men (individuals with alcohol consumption >40 g/d for females or >60
g/d for males had been excluded a priori).
dAdjusted OR, 19.8; 95% CI, 4.6–84.1.
eP < .01 (both univariable and multivariable analysis).
fAdjusted OR, 2.1; 95% CI, 1.3–3.2.
gP < .02 (both univariable and multivariable analysis).
hAdjusted OR, 9.5; 95% CI, 1.2–76.6.
iAdjusted OR, 14.8; 95% CI, 5.4–40.4. All multivariable analyses were adjusted for age, sex, BMI, presence of diabetes
mellitus, and mean alcohol consumption.







Ryear and only 21% received regular liver ultrasound
examinations.
Serum liver enzymes were increased above the sex-
specific upper limit of normal (ULN) in only a minority
of Pi*ZZ carriers: 19.1% alanine aminotransferase (ALT),
12.7% AST, 23.7% GGT, and 8.6% alkaline phosphatase
(Supplementary Table 3). Themean serumALT, AST, and GGT
activitieswerehigher inPi*ZZcarriers thannon-carriers (80%
vs 66%of ULN, 74%vs 62%of ULN, 100%vs 58%of ULN; all,
P < .001) (Figure 2A–C). The differences in cholestatic
markers were less obvious (alkaline phosphatase: 66% vs
60% of ULN, P¼ .003; bilirubin: 51% vs 47% of ULN, P¼ .11)
(Figure 2D–E). Surrogate markers of advanced liver disease,such as platelet count (marker of portal hypertension), aswell
as albumin and international normalized ratio (markers of
hepatic synthesis) were within the normal range in most
patients (Supplementary Table 3). Nevertheless, Pi*ZZ
carriers displayed lower platelet count and albumin, but
higher international normalized ratio values thannon-carriers
(all, P < .001) (Figure 2F; Supplementary Table 3). Notably,
Pi*ZZ carriers also hadhigher hemoglobin levels, thatmight be
due to a higher burden of lung disease (Supplementary
Table 3). All of the parameters mentioned remained signifi-
cant in a multivariable analysis adjusting for age, sex, body
mass index, presence of diabetes mellitus, and mean alcohol
consumption (all, P < .05) (Supplementary Table 3).
Figure 2. Liver-related and
metabolic parameters in
carriers homozygous for
the AAT Pi*Z variant
(Pi*ZZ) and Pi*Z non-
carriers. After fasting, 403
Pi*ZZ carriers and 234
non-carriers without
known liver disease were
subjected to laboratory
analysis. (A–E) Scatter
plots depict liver enzyme
serum activities normal-
ized to the sex-specific
ULN that is marked as a
dotted line. (F) Scatter
plots of platelet count in
the blood (lower limit of
normal is marked as a
dotted line). (G–H) Scatter
plots of absolute serum
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LIVERTaken together, serum liver enzymes were significantly
higher in Pi*ZZ carriers compared to non-carriers, but only
a minority of Pi*ZZ carriers had values above the ULN.Non-Invasive Liver Fibrosis Tests in Pi*ZZ Carriers
TE revealed that the mean LSMs were higher in Pi*ZZ
carriers compared to non-carriers (6.7 ± 5.8 kPa vs 4.6 ± 1.7kPa, P < .001) (Table 1 and Figure 3A). In line, 23.6% of
Pi*ZZ carriers vs 6.4% of non-carriers displayed LSM 7.1
kPa, suggesting the presence of significant liver fibrosis
(fibrosis stage of at least 2) (P < .001) (Table 1). The dif-
ference between carriers and non-carriers was even more
pronounced when considering subjects with LSM10.0 kPa,
suggesting the presence of advanced fibrosis stage of at least
3 (13.6% vs 1.3%; adjusted OR, 19.8; 95% CI, 4.6–84.1).
Figure 3. Non-invasive liver fibrosis and steatosis parameters in carriers homozygous for the AAT Pi*Z variant (Pi*ZZ) and Pi*Z
non-carriers. After fasting, 403 Pi*ZZ carriers and 234 non-carriers without known liver disease (exploratory cohort) were
subjected to laboratory analysis and non-invasive assessment by TE (FibroScan). (A) Scatter plot of median liver stiffness
determined by TE. The dotted lines indicate the following etiology-unspecific cutoff levels: 7.1 kPa (suggestive of fibrosis stage
2) and 10.0 kPa (suggestive of fibrosis stage 3). (B) Scatter plots of APRI values, an indirect fibrosis marker in the blood. The
dotted lines indicate the following etiology-unspecific cutoff levels: 0.5 (suggestive of fibrosis stage 2) and 1.0 (suggestive of
fibrosis stage 3). (C) Scatter plots of HepaScore values, a direct fibrosis serum marker. The dotted lines indicate the following
etiology-unspecific cutoff levels: 0.48 (suggestive of fibrosis stage 2) and 0.72 (suggestive of fibrosis stage 3). (D) Scatter
plot of CAP, a surrogate parameter of liver steatosis determined by TE. The dotted lines indicate the following etiology-
unspecific cutoff levels: 248 dB/m (suggestive of steatosis stage 1), 268 dB/m (suggestive of steatosis stage 2), and
280 dB/m (suggestive of steatosis stage 3). Univariable (E) and multivariable (F) analyses depicts the odds of Pi*ZZ carriers
(compared to non-carriers) to display values suggestive of advanced fibrosis. The adjustments were made for sex, age, body
mass index, presence of diabetes mellitus, and mean alcohol consumption.
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LIVERIn agreement with LSM, APRI—a serum-based, indirect
liver fibrosis test—showed higher levels in Pi*ZZ carriers
vs non-carriers (0.41 ± 0.36 units vs 0.27 ± 0.12 units;
P< .001) (Table 1 and Figure 3B). Comparable APRI and LSM
values were seen in the national subcohorts (Supplementary
Table 1). Of Pi*ZZ carriers, 19.6% had APRI values 0.50
units, suggesting the presence of significant liver fibrosis,
compared to 5.4% of non-carriers (P < .001) (Table 1).
Similarly, 4.5% of Pi*ZZ carriers vs 0.5% of non-carriers
displayed APRI 1.0 units, suggesting the presence of
advanced liver fibrosis (adjusted OR, 9.5; 95% CI, 1.2–76.6).
The HepaScore, a serum-based, direct liver fibrosis test,
revealed higher levels in Pi*ZZ carriers compared to non-
carriers (0.43 units ± 0.32 vs 0.25 ± 0.21 units; P < .001)
(Table 1 and Figure 3C). HepaScore values suggestive of
significant and advanced liver fibrosis were also more com-
mon in Pi*ZZ carriers vs non-carriers (significant fibrosis
[HepaScore 0.48 units]: 36.3% vs 13.5%; P < .001 and
advanced fibrosis (HepaScore 0.72 units): 25.6% vs 4.1%;
P < .001; adjusted OR, 14.8; 95% CI, 5.4-40.4, respectively)
(Table 1). The 3 liver fibrosis tests correlated reasonably well
with each other (LSM and APRI: r ¼ .46, P < .001; LSM and
HepaScore: r ¼ .38, P < .001; APRI and HepaScore: r ¼ .43,
P < .001) (Supplementary Figure 1) and collectively allowed
a convenient triage of Pi*ZZ carriers. For example, based on
APRI and LSM, 68.1% of Pi*ZZ carriers were unlikely to have
significant liver fibrosis (ie, were classified as no or minimal
fibrosis [F0–1] by both scores). On the other hand, 10.9% and
3.1% had values consistent with significant, advanced
fibrosis, based on both APRI and LSM, respectively.
While our study cannot offer a precise calculation of
liver fibrosis burden, it suggests that 20%–36% of Pi*ZZ
carriers had significant liver fibrosis and that the odds for
having advanced liver fibrosis were 9–20 times higher in
Pi*ZZ carriers vs non-carriers (Figure 3E and F).
Confirmatory Pi*ZZ Cohort
To further corroborate our findings, we took advantage
of an independent Pi*ZZ cohort that was recruited in the
same manner as the exploratory cohort. This confirmatory
cohort consisted of 151 Pi*ZZ patients from 4 European
countries, and all national subcohorts had a similar de-
mographic pattern (Supplementary Table 2). Moreover,
there were no major differences in the demographic char-
acteristics and the fibrosis test measures between the
confirmatory and the exploratory cohorts (Supplementary
Tables 1 and 2). Because the majority of patients in our
study were recruited in Germany, we pooled the exploratory
and confirmatory cohorts to compare German and non-
German recruits. While German Pi*ZZ carriers were some-
what older and had a stronger AATD-related lung disease
than non-German recruits, no other relevant differences
between groups were detected (Supplementary Table 4).
Non-Invasive Steatosis Assessment in Pi*ZZ
Carriers and Steatosis Assessment in Pi*Z-
Overexpressing Mice
CAP, an established surrogate of liver steatosis,28 revealed
higher mean values in Pi*ZZ carriers vs non-carriers(267 ± 57 dB/m vs 246 ± 56 dB/m; P < .001) (Table 1).
Accordingly, more Pi*ZZ carriers than non-carriers
displayed CAP, suggesting the presence of mild steatosis
(CAP 248 dB/m: 61.1% vs 48.2%, respectively; P ¼ .002)
and severe steatosis (CAP 280 dB/m: 38.8% vs 28.2%,
respectively; P ¼ .012; adjusted OR, 2.1; 95% CI, 1.4–3.3)
(Table 1 and Figure 3D). All results remained significant in a
multivariable analysis (all, P < .01) (Table 1).
To investigate whether these differences in CAP values
constitute a direct consequence of Pi*Z retention in the liver,
we examined transgenic mice overexpressing the human
Pi*Z variant and their non-transgenic littermates. On histo-
logic sections, Pi*Z-overexpressing mice showed more
steatosis than their non-transgenic littermates (Figure 4A).
To quantify the extent of steatosis, we performed Oil Red O
staining and assessment of hepatic triglyceride content.
Both analyses revealed a stronger lipid accumulation in
Pi*Z-overexpressing mice compared to non-transgenic
littermates (Figure 4B and C). In contrast, no difference in
serum cholesterol or serum triglyceride levels was observed
(Figure 4D and E). Because Pi*Z-overexpressing mice were
shown to have decreased levels of hepatocyte nuclear factor
4a, which is essential for maintenance of liver homeosta-
sis,36,37 we analyzed its expression as well as the expression
of its downstream targets involved in lipid secretion.
Notably, hepatocyte nuclear factor 4a, microsomal
triglyceride transfer protein, apolipoprotein A4, and apoli-
poprotein C2 were all significantly down-regulated in
Pi*Z-overexpressing mice compared to their non-transgenic
littermates (Figure 4F).
The differences in hepatic steatosis in both humans and
mice prompted us to evaluate serum lipid parameters. Pi*ZZ
carriers had, compared to non-carriers, markedly reduced
serum triglyceride (102 ± 52 mg/dL vs 125 ± 70 mg/dL;
P < .001) and very-low-density lipoprotein cholesterol
concentrations (9.6 ± 3.4 mg/dL vs 11.5 ± 4.2 mg/dL;
P < .001). Only a minimal, but a significant, difference in
low-density lipoprotein cholesterol (P ¼ .03) and no
significant alterations in total cholesterol were found
(Figure 2G and H and Supplementary Table 3). Multivariable
adjustment confirmed these differences (all, P < .001)
(Supplementary Table 3). While 58% of Pi*ZZ carriers
received AAT augmentation therapy, the observed findings
regarding liver fibrosis and steatosis, as well as changes in
lipid parameters, were also detected when only Pi*ZZ in-
dividuals without augmentation therapy were considered
(Supplementary Table 5).Impact of Age, Lung Involvement, and Sex on
Pi*ZZ-Related Liver Alterations
The availability of a large, real-life cohort of Pi*ZZ
carriers allowed us to assess whether age, sex, and pres-
ence of lung disease have any association with the extent
of liver fibrosis. As expected, lung-related parameters
revealed an age-dependent deterioration of pulmonary
function that was evident in higher CAT values, higher
rates of LTOT, and subsequently higher need for
AAT augmentation therapy (Supplementary Table 6). In
Figure 4. Extent of liver steatosis and expression of steatosis-related genes in untreated mice overexpressing the AAT Pi*Z
variant (PiZ) and their non-transgenic littermates (NT). Fourteen transgenic, Pi*Z-overexpressing mice and 14 NT littermates, all
8–12 weeks of age, were histologically assessed for the extent of liver steatosis. (A) Representative images of liver sections
stained with H&E (upper panel) or Oil Red O (ORO, lower panel). Scale bars ¼ 20 mm. (B) Morphometric quantification of ORO
staining. (C) Hepatic triglyceride content was determined biochemically. Serum cholesterol levels (E) and serum triglyceride
levels (D) in Pi*Z-overexpressing mice and their non-transgenic littermates. (F) The relative expression of hepatic nuclear factor
4a (HNF4a), apolipoprotein A4 (ApoA4), microsomal triglyceride transfer protein (MTTP), and apolipoprotein C2 (ApoC2) were
analyzed via reverse transcription polymerase chain reaction. L7 (mouse ribosomal protein) gene was used as a loading
control. Mean expression in NT littermates was arbitrarily set as 100% and all other levels represent a ratio. chol., cholesterol;
PiZ, mice overexpressing the human AAT Pi*Z variant; TG, triglycerides.
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LIVERparticular, CAT values had a moderate correlation with
age (r ¼ .42, P < .001) (Supplementary Figure 2A) and
the need for LTOT was more prevalent in older Pi*ZZ
carriers (Supplementary Figure 2B). In contrast, although
LSM 7.1 kPa were less frequent in Pi*ZZ carriers <50
years of age, no relevant correlation between age and
LSM was seen (Supplementary Figure 2C and D and
Supplementary Table 6). A comparably weak relation
with age distribution was noted both for APRI and Hepa-
Score (Supplementary Figure 2E–H and Supplementary
Table 6).
To assess a potential association between lung disease
and liver fibrosis, we compared CAT values with the 3
available non-invasive fibrosis scores. No significant corre-
lation between CAT scores and LSM or APRI values were
found (Figure 5A and C, Supplementary Figure 3A–D). In
contrast, HepaScore and CAT had a weak, but significant,
correlation (Figure 5E, Supplementary Figure 3E and F),
which is likely due to the fact that HepaScore includes age as
one parameter and because of that, older patients, who
typically have a worse lung function, also harbor higher
HepaScores.
As the presence of advanced Pi*ZZ-related lung
disease with altered right heart function may affect LSM
values, we analyzed the results of non-invasive liver
fibrosis assessments in individuals with and without need
for LTOT. Both groups had similar LSM (Figure 5B).
Moreover, the observed correlations among LSM, APRI,
and HepaScore were similar in Pi*ZZ patients with and
without LTOT (Supplementary Figure 4), thereby, clearly
indicating that the presence of advanced lung disease did
not compromise the usefulness of LSM. Similarly to LSM,
neither APRI nor HepaScore values differed significantly
in Pi*ZZ carriers with and without LTOT (Figure 5D and
F). Collectively, using 3 different non-invasive liver
fibrosis tests, we demonstrated that Pi*ZZ carriers had no
significant correlation between the burden of lung and
liver disease.
Next, we studied the association between sex and
liver-related parameters. Male Pi*ZZ carriers displayed
higher sex-specific ALT, GGT, and bilirubin serum activ-
ities than female Pi*ZZ carriers (86% vs 72% of ULN,
115% vs 81% of ULN, 59% vs 44% of ULN, respectively;
all, P < .05) (Supplementary Table 7). Moreover, Pi*ZZ
men had higher LSM, APRI, HepaScore, and CAP values
compared to their counterparts (7.8 ± 7.0 kPa vs 5.5 ±
3.5 kPa, 0.49 ± 0.45 units vs 0.30 ± 0.18 units, 0.54 ±
0.32 units vs 0.30 ± 0.27 units, and 277 ± 59 dB/m
vs 254 ± 52 dB/m, respectively; all, P < .001)
(Supplementary Table 7). Accordingly, Pi*ZZ men dis-
played a markedly higher risk for LSM 7.1 kPa (unad-
justed OR, 3.9; 95% CI, 2.3–6.7) (Supplementary Table 8
and Supplementary Figure 5A), APRI 0.50 units
(unadjusted OR, 5.7; 95% CI, 2.9–10.9) (Supplementary
Table 9 and Supplementary Figure 6A), and HepaScore
0.48 units (unadjusted OR, 4.1; 95% CI, 2.3–7.4)
(Supplementary Table 10 and Supplementary Figure 7A).
Similarly, men had lower platelet counts and higher in-
ternational normalized ratio values (214.7 ± 59.7 G/L vs253.1 ± 69.7 G/L, and 1.04 ± 0.09 vs 0.99 ± 0.08,
respectively; both, P < .001) (Supplementary Table 7). All
comparisons remained significant in a multivariable
analysis (all, P < .01) (Supplementary Table 7 and not
shown).
Together, male sex is associated with a more prominent
liver disease, while age has no, or a less obvious, effect.
Moreover, the extents of lung and liver disease did not
correlate with each other.Additional Factors Associated With the Presence
of Significant Liver Fibrosis
Obese Pi*ZZ carriers, defined as body mass index 30
kg/m2, were more likely to display LSM 7.1 kPa
(Supplementary Table 8 and Supplementary Figure 5B), but
neither to have APRI 0.50 units (Supplementary Table 9
and Supplementary Figure 6B) nor HepaScore 0.48 units
(Supplementary Table 10 and Supplementary Figure 7B).
AST and GGT serum levels were higher and platelet counts
were lower in Pi*ZZ carriers with vs without LSM 7.1 kPa
(Supplementary Table 8), APRI 0.50 units vs <0.50 units
(Supplementary Table 9), and HepaScore 0.48 units vs
<0.48 units (Supplementary Table 10). Elevated GGT (ie,
above the sex-specific ULN) conferred a particularly strong
risk to have LSM 7.1 kPa (unadjusted OR, 5.1; 95% CI, 3.1–
8.4) (Supplementary Table 8 and Supplementary Figure 5C)
and APRI 0.50 units (unadjusted OR, 5.1; 95% CI, 3.0–8.7)
(Supplementary Table 9 and Supplementary Figure 6C).
Similarly, reduced platelets (ie, platelet count <150 G/L)
markedly predisposed to LSM 7.1 kPa (OR, 5.7; 95% CI,
2.7–11.8) (Supplementary Table 8 and Supplementary
Figure 5D), APRI 0.50 units (OR, 31.0; 95% CI, 12.2–
79.0) (Supplementary Table 9 and Supplementary
Figure 6D), and HepaScore 0.48 units (OR, 5.2; 95% CI,
1.8–15.3) (Supplementary Table 10 and Supplementary
Figure 7D).
As detailed here, we demonstrated that demographic
parameters as well as laboratory values help to estimate
the individual risk for presence of significant liver fibrosis
and may therefore be used in patient counseling. To
facilitate that, we determined the frequency of elevated
non-invasive liver fibrosis tests in clinically relevant Pi*ZZ
subpopulations (Figure 6). These data revealed a low risk
of significant liver fibrosis (ie, LSM 7.1 kPa, APRI 0.50
units, and HepaScore 0.48 units) in young women as well
as women with normal serum GGT, AST, or ALT. Males
younger than 50 years old constituted the male subpop-
ulation with the lowest likelihood of increased liver
fibrosis test values. Among serum parameters, elevated
serum ALT, AST, or GGT was associated with higher
occurrence of fibrosis test values suggestive of significant
liver fibrosis. Pi*ZZ carriers with thrombocytopenia had,
regardless of their sex, a high likelihood of significant liver
fibrosis.
Collectively, our study uncovered that male sex; age
older than 50 years; elevated ALT, AST, and GGT; and
reduced platelet count associated with non-invasive liver
fibrosis tests suggest the presence of significant fibrosis.
Figure 5. Relationship be-
tween lung function and
liver fibrosis in homozy-
gous carriers of the AAT
Pi*Z variant (Pi*ZZ). Four
hundred and three Pi*ZZ
carriers were analyzed
by 3 independent, non-
invasive liver fibrosis tests
(TE [FibroScan], APRI, and
HepaScore), while the lung
function was estimated via
the need for LTOT, as well
as CAT (a measure of lung
function-related quality of
life). Scatter plots display
the values of non-invasive
fibrosis scores in patients
with different CAT values
(A, C, and E), as well as
individuals with/without
LTOT (B, D, and F).









Our study represents, to our knowledge, the largest
systematic evaluation of the liver phenotype in Pi*ZZ
carriers and the associated clinical contexts. We used 3
independent, non-invasive fibrosis tests that, compared to
liver biopsy, are more suitable for long-term disease moni-
toring26,27 and for recruitment of a real-life population,
including individuals without clinically relevant liver
involvement.
Using these tests, the presence of significant liver
fibrosis was suggested in 20%–36% and the presence of
advanced liver fibrosis in 5%–26% of Pi*ZZ study partici-
pants. Moreover, Pi*ZZ carriers had 9–20 times higher odds
than non-carriers to have liver fibrosis test results that
indicate advanced liver fibrosis. While these numbers
clearly document the vulnerability of Pi*ZZ carriers for liverdisease, the frequencies are lower than former reports
suggesting that up to 43% of Pi*ZZ individuals may develop
cirrhosis,22,38 or a recent TE-biopsy study suggesting that
35% have significant fibrosis. Additionally, the observed
risk for presence of advanced liver fibrosis appears lower
than the reported odds of Pi*ZZ subjects to receive liver
transplantation.39
These differences are not surprising, given the limited
size of the previously analyzed cohorts and potential bias
that may arise due to the recruitment via liver biopsy.
Additionally, given that the occurrence of Pi*Z variant seems
to promote the decompensation of end-stage liver disease,40
the odds requiring a liver transplantation may surpass the
risk to form advanced liver fibrosis. On the other hand, the
careful screening for hepatic comorbidities and exclusion of
individuals with previously existing liver disease and those
Figure 6. Rate of Pi*ZZ
carriers with significant
liver fibrosis according to
LSM, APRI, and Hepa-
Score among specific
subpopulations. Relative
frequencies (%) are shown
and visualized by a color
coding (right panel). The
cutoffs for liver stiffness




the presence of significant
fibrosis (F2). Plt, platelets.
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LIVERwith potentially harmful alcohol consumption may have led
to underestimation of the liver disease burden occurring in
the general population. While the current article describes
the baseline evaluation of the study participants, a longitu-
dinal follow-up is being carried out to determine the rate of
liver fibrosis development, hepatic decompensation, or he-
patocellular carcinoma formation.
A limitation of our study is that the extent of liver
fibrosis was evaluated by non-invasive methods only. To
minimize the associated risks, we used 3 independent tests
and carried out an extensive cross-validation that helped us
to address potential caveats. For example, TE values tended
to be higher in obese individuals, whereas the other fibrosis
tests did not reveal an obvious relationship between both
parameters. This is in line with the observation that TE mayoverestimate the extent of liver fibrosis in overweight in-
dividuals.41 On the other hand, previous studies support the
TE findings in that they suggested a promoting effect of
obesity on liver disease development in Pi*ZZ carriers.42,43
Another limitation of LSM, which has been carefully
addressed in our study, is its potential affection by hepatic
congestion (eg, caused by right-sided heart failure).44
Although we cannot fully exclude this possibility in
selected patients, several analytical outcomes argue against
this as a major confounding factor. In particular, we could
not detect any differences in LSM between Pi*ZZ carriers
with and without LTOT (Figure 5), despite the fact that the
need for LTOT is commonly associated with right-sided
heart failure. Moreover, the correlation between the
applied fibrosis tests was similarly robust in patients with







Rand without need for LTOT (Supplementary Figure 4).
Finally, there was no obvious relationship between LSM and
CAT values (Figure 5 and Supplementary Figure 3), even
though CAT constitutes a well-validated measure of lung
function-related quality of life. The parallel assessment of
TE, APRI, and HepaScore values revealed a moderate cor-
relation between the former 2, whereas the correlations
with the HepaScore were less robust. Accordingly, previous
studies demonstrated that a2-macroglobulin, a component
of the HepaScore, is elevated in Pi*ZZ carriers.45 This
finding, together with the fact that the HepaScore had a
weaker association with serum liver enzymes than the other
scores, suggests that it might be a suboptimal measure of
liver fibrosis in this population.
CAP indicated that Pi*ZZ carriers have more pronounced
liver steatosis, which is in line with a published liver biopsy
series of Pi*ZZ adults.46 The simultaneous presence of
decreased triglyceride and very-low-density lipoprotein
cholesterol levels suggest that Pi*Z accumulation in the
endoplasmic reticulum affects lipid metabolism of this
subcompartment. This hypothesis was in part strengthened
by our murine experiments suggesting that intrahepatocytic
Pi*Z accumulation might result in increased hepatic tri-
glyceride content. In particular, an impaired hepatocyte
nuclear factor 4a signaling observed in Pi*Z-overexpressing
mice may result in impaired lipoprotein assembly and lipid
secretion.36,37 An alternative explanation is that hepatic
steatosis arises from proteotoxic stress, a known result of
intrahepatocytic Pi*Z accumulation.47–49 In this respect, an
overwhelmed lipid autophagy due to the need to degrade
excess Pi*Z, as well as the reported interaction of Pi*Z with
lipoprotein particles might be of relevance.50,51 Therefore,
further studies are needed to delineate the precise factors
contributing to hepatic steatosis in both Pi*Z-
overexpressing mice and Pi*ZZ humans.
With regard to monitoring individual Pi*ZZ carriers, our
data corroborate and extend the following observations:
irrespective of a Pi*ZZ carrier’s age, liver enzymes are
elevated in only a minority of them24,25; and males are at a
higher risk for an advanced liver disease developing than
females (Figure 3A).22,52 With regard to the latter, murine
data demonstrate that males synthesize more AAT and that
testosterone treatment of female Pi*Z-overexpressing mice
increases AAT expression.53 Hence, in case of Pi*Z mutation,
increased Pi*Z synthesis might result in progressive
fibrogenesis.
Our evaluation of Pi*ZZ carriers also yielded the
following novel and less expected findings:
1. Unlike what has been reported previously,54,55 we did
not see a relevant correlation between the severity of
lung and liver involvement (Figure 5). While APRI and
TE did not correlate with lung function significantly, a
weak correlation with HepaScore might be due to age,
a component of the HepaScore, as a confounding
factor.
2. Age younger than 50 years was associated with lower
rates of significant liver fibrosis in males but, otherthan what has been reported previously,5,23 age
younger than 50 years had no major impact in fe-
males. This finding most likely explains why there is
no obvious linear correlation between liver fibrosis
and age (Supplementary Figure 2C–F).
3. Among routinely assessed laboratory parameters,
elevated GGT levels were particularly predictive for
the presence of liver fibrosis (Supplementary
Figures 5–7C). This is not surprising because GGT
causally associates with obesity and plays an impor-
tant role in defense against oxidative stress and is
therefore an established marker of metabolic liver
disease.56,57 Similarly, the observed usefulness of
platelet count (Supplementary Figures 5–7D) is well
in line with its known association with extent of
portal hypertension.58
4. In contrast to a previous report, ALT, AST, and GGT
reasonably well discriminated between patients with
and without significant liver fibrosis, and when within
normal range, might be particularly useful to identify
females at low risk of fibrosis. On the other hand, they
are not sufficient to rule out significant fibrosis in
males (Figure 6).
In summary, our large, international cohort defined the
liver phenotype of Pi*ZZ adults and uncovered associated
metabolic alterations. The high odds of Pi*ZZ carriers to
develop a clinically relevant liver affection warrant a regular
assessment of liver enzymes and of liver fibrosis. As liver
enzymes were regularly determined in only 45% of our
Pi*ZZ study participants, and as liver fibrosis was assessed
in a negligible minority only, the presented data should raise
awareness for this neglected condition. Simultaneous use of
3 non-invasive fibrosis tests clearly delineated the useful-
ness of commonly available laboratory values, including
AST, GGT, and platelets, in the initial assessment of the Pi*ZZ
liver phenotype. In addition, a calculation of APRI provides
another widely available tool in the assessment of these
individuals. The ongoing, longitudinal evaluation of this
largest prospective Pi*ZZ cohort will be useful to gain
further insights into the process of disease development.
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Supplementary Methods
Ethical Statement
Ethical approval was provided by the Institutional Re-
view Board of Aachen University (EK 173/15), as well as by
the Institutional Ethics Committees of the participating
centers (ie, Homburg and Berlin from Germany; Vienna,
Innsbruck, and Salzburg from Austria; Odense from
Denmark; Madeira, Lisbon, and Porto from Portugal; Bar-
celona from Spain; Cambridge from UK; and Bern from
Switzerland). The study was conducted according to the
Declaration of Helsinki (Hong Kong Amendment), as well as
Good Clinical Practice (European guidelines), and was
registered with ClinicalTrials.gov (NCT02929940).
Recruitment of Study Population
Pi*ZZ carriers have been recruited during an awareness
campaign (for details see above) that was supported via an
AATD liver-related website (www.alpha1-liver.eu), a tele-
phone hotline, a presence on social media, talks at patient
meetings, as well as contributions to patient-centered pe-
riodicals in various countries. Additional carriers were
attracted by the University Hospital Aachen as the coordi-
nating center for AATD-related liver disease of 2 European
initiatives (European Association for the Study of the Liver
Registry Group “Alpha1-Liver” and European Reference
Network “Rare-Liver”). For the exploratory cohort, both
carriers and non-carriers had been recruited in the period
from April 1, 2015 through September 30, 2017 in 7
different countries (Supplementary Table 1). For the
confirmatory cohort, Pi*ZZ carriers had been recruited from
October 1, 2017 through April 30, 2018 in four different
countries (Supplementary Table 2).
Every participant filled out standardized questionnaires
including information on demographic parameters, relevant
comorbidities, and lung-related (eg, CAT, need for LTOT)
and liver-related health (eg, surveillance and alcohol
consumption).
Assessment of Liver Disease
In all participants, the presence of a previously diag-
nosed liver disease has been excluded by personal inter-
view (ie, no established diagnosis of chronic liver disease
and no history of liver resection or liver transplantation)
and laboratory workup. Chronic viral hepatitis B and C were
excluded serologically. Serum levels of ferritin and trans-
ferrin saturation were determined to evaluate the presence
of hereditary hemochromatosis. For every individual pa-
tient, drinking habits were assessed in a face-to-face inter-
view evaluating the long-term drinking habits and thereby
the average weekly number of alcoholic drinks was deter-
mined. Consequently, the mean amount of alcohol
consumed per week was calculated and used for further
analysis. Patients with self-reported pathologic alcohol
consumption (>40 g/d for women and >60 g/d for men)
have been excluded (5 Pi*ZZ carriers and 1 non-carrier).
Finally, patients with elevated ALT or AST >5 the sex-
specific ULN or alkaline phosphatase >2 the sex-specific
ULN on the day of recruitment have been excluded (2
Pi*ZZ carriers and 0 non-carrier) because marked elevation
of these parameters precludes a reliable assessment by TE.
Isoelectric focusing and genotyping were carried out by the
corresponding national AAT reference laboratories, as
described.1
On the day of inclusion, venous blood was obtained,
centrifuged, aliquoted, and stored at –80C. Presence of
hepatitis B surface antigen, anti-hepatitis C virus antibodies
(Cobas e 601; Roche Diagnostics, Mannheim, Germany), and
serum very-low-density lipoprotein cholesterol (Hydrasys,
Sebia, Fulda, Germany) were determined by appropriate
assays. a2-Macroglobulin (BN ProSpec; Siemens, Marburg,
Germany) and hyaluronic acid (COBAS c501; Wako Chem-
icals, Neuss, Germany) were measured in the serum to
calculate the HepaScore. All tests have been approved for
use in clinical routine.
Pi*Z-Overexpressing Mice and Quantification of
Hepatic Steatosis
All mice were kept on standard diet in the animal facility
of Rheinisch-Westfälische Technische Hochschule Aachen
University (Aachen, Germany). Liver tissues were dissected
as described previously.2 The extent of lipid accumulation
was evaluated via Oil Red O staining. Briefly, liver speci-
mens were embedded in Tissue-Tek Compound (Sakura,
Torrance, CA), snap-frozen, and cut into 5-mm thin sections.
The sections were fixed in 10% formalin for 5 minutes at
room temperature and rinsed first with tap water, then with
60% isopropanol (Sigma-Aldrich, St Louis, MO). Samples
were incubated in fresh Oil Red O working solution for 15
minutes at room temperature and the unbound dye was
removed with 60% isopropanol. The counterstaining was
carried out with hematoxylin. The pictures were taken with
the Zeiss light microscope ImagerA2 (Zeiss, Göttingen,
Germany) and the amount of lipids was quantified with
ImageJ software (National Institutes of Health, Bethesda,
MD). To determine the hepatic triglyceride content, liver
tissues were incubated in ethanolic KOH overnight at 55C.
The resulting liver homogenates were mixed with a 1:1
EtOH/H2O solution and centrifuged at 14,000 rpm for 5
minutes to remove the debris. Then 1M MgCl2 was added
and the mixture was incubated on ice for 10 minutes. After
additional centrifugation, the supernatants were collected
and triglyceride amount was analyzed at the Department of
Clinical Chemistry of Aachen University Hospital. The con-
centration was normalized to wet liver weight. Serum tri-
glycerides and cholesterol levels were also analyzed at the
Department of Clinical Chemistry of Aachen University
Hospital. Animal handling was carried out in accordance
with the German law for welfare of laboratory animals.
RNA was isolated from 2-month-old mouse livers via
RNeasy mini isolation kit (Qiagen, Hilden, Germany). The
RNA samples were translated to complementary DNA with
M-MLV reverse transcriptase kit (Promega, Madison, WI).
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Supplementary Figure 1. Correlation of non-invasive liver fibrosis parameters in homozygous carriers of the AAT Pi*Z variant
(Pi*ZZ). The dotted lines represent the proposed cutoffs for significant fibrosis (liver stiffness: 7.1 kPa, APRI: 0.50 units,
HepaScore: 0.48 units) and advanced fibrosis (liver stiffness: 10 kPa, APRI 1.00, HepaScore: 0.72). (A) Correlation of liver
stiffness (log10) and APRI (log2). (B) Correlation of liver stiffness (log10) and HepaScore. (C) Correlation of APRI (log2) and
HepaScore.
The relative expression of genes of interest was determined
using specific primers for HNF4a (hepatocyte nuclear factor
4a, F: GGC CAA GAT TGA CAA CCT GC, R: TGA GAG GGC ATC
GTG TTA GC), ApoA4 (apolipoprotein A-IV, F: ATG CCA AGG
AGG CTG TAG AAC, R: AAA GGG CAC CAG CTT GTT GT),
ApoC2 (apolipoprotein C-II, F: AAC CAG GAA GAT GAC TCG
GG, R: AAA TGC CTG CGT AAG TGC TC), and Mttp (micro-
somal triglyceride transfer protein, F: AGA TGG ACG CCA
GCT TTT GTT, R: TCC TTT GCC CCC ATC AAG AA). The
messenger RNA expression was normalized to the levels of
the housekeeping ribosomal gene L7 (ribosomal protein, F:
Supplementary References
1. Greulich T, Ottaviani S, Bals R, et al. Alpha1-antitrypsin
deficiency—diagnostic testing and disease awareness
in Germany and Italy. Respir Med 2013;107:1400–1408.
2. Guldiken N, Kobazi Ensari G, Lahiri P, et al. Keratin 23 is
a stress-inducible marker of mouse and human ductular
reaction in liver disease. J Hepatol 2016;65:552–559.
GAA AGG CAA GGA GGA AGC TCA TCT, R: AAT CTC AGT GCG
GTA CAT CTG CCT).
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Supplementary Figure 2. Impact of age on lung and liver phenotype in carriers homozygous for the AAT Pi*Z variant (Pi*ZZ).
Four hundred and three Pi*ZZ carriers were analyzed by 3 independent, non-invasive liver fibrosis tests (TE [FibroScan], APRI,
and HepaScore), while the lung function was estimated via the need for LTOT, as well as the CAT (a measure of lung function-
related quality of life). (A) Linear correlation between age and CAT score. (B) Percentage of Pi*ZZ carriers needing LTOT in the
highlighted age groups. (C, E, G) Linear correlation between age and non-invasive liver fibrosis parameters (D, E, H) Per-
centage of Pi*ZZ carriers with non-invasive test values suggesting the presence of significant liver fibrosis (LSM 7.1 kPa;
APRI 0.50 units; HepaScore 0.48 units) in the depicted age groups. Notably, the analysis of the relation between Hepa-
Score and age is confounded by the fact that age is a component of the HepaScore.
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Supplementary Figure 3. Association of non-invasive fibrosis tests and COPD assessment test in carriers homozygous for
the AAT Pi*Z variant (Pi*ZZ). Four hundred and three Pi*ZZ carriers filled out standardized questionnaires and underwent non-
invasive assessment of liver fibrosis via laboratory analysis and transient elastography. (A, C, E) Linear correlation of CAT score
with liver stiffness, APRI, and HepaScore values. (B, D, F) Liver stiffness, APRI, and HepaScore values. in Pi*ZZ carriers with
low, medium, and high CAT scores (CAT <10, 10–19, and 20, respectively) indicating the severity of chronic obstructive
pulmonary disease–associated symptoms.
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Supplementary Figure 4. Correlation of non-invasive liver fibrosis parameters in homozygous Pi*ZZ carriers with and without
LTOT. The dotted lines represent the proposed cutoffs for significant fibrosis (liver stiffness: 7.1 kPa, APRI: 0.50, HepaScore:
0.48) and advanced fibrosis (liver stiffness: 10 kPa, APRI 1.00, HepaScore: 0.72). (A, D) Correlation of liver stiffness (log10) and
APRI (log2) in Pi*ZZ carriers with and without LTOT. (B, E) Correlation of liver stiffness (log10) and HepaScore in Pi*ZZ carriers
with and without LTOT. (C, F) Correlation of APRI (log2) and HepaScore in Pi*ZZ carriers with and without LTOT.
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Supplementary Figure 5. Predictors of significant liver fibrosis as assessed by TE in homozygous carriers of the AAT Pi*Z
variant (Pi*ZZ). Four hundred and three Pi*ZZ carriers were subjected to clinical evaluation, laboratory analysis, and non-
invasive assessment by TE (FibroScan). (A, B) Scatter plots of median liver stiffness determined by TE in women and men
(A) and in non-obese (body mass index [BMI] <30 kg/m2) vs obese (BMI 30 kg/m2) individuals (B). (C) Scatter plot of liver
stiffness in Pi*ZZ carriers with serum GGT activities within nomal reference range vs those with serum GGT activities above the
sex-specific ULN. (D) Scatter plot of liver stiffness in Pi*ZZ carriers with and without thrombocytopenia with a cutoff of 150 G/L.
The dotted lines represent the following etiology-unspecific cutoff levels: 7.1 kPa (suggestive of fibrosis stage 2), 10.0 kPa
(suggestive of fibrosis stage 3), and 13.0 kPa (suggestive of fibrosis stage 4). Plt, platelets.
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Supplementary Figure 6. Predictors of significant liver fibrosis as assessed by APRI in homozygous carriers of the AAT Pi*Z
variant (Pi*ZZ). Four hundred and three Pi*ZZ carriers and 234 non-carriers (exploratory cohort) were subjected to clinical
evaluation and laboratory analysis. (A, B) Scatter plots of APRI values in women and men (A) and in non-obese (BMI <30 kg/
m2) vs obese (BMI 30 kg/m2) individuals. (C) Scatter plot of APRI levels in Pi*ZZ carriers with serum GGT activities within
normal reference range vs those with serum GGT activities above the sex-specific ULN. (D) Scatter plot of APRI values in Pi*ZZ
carriers with and without thrombocytopenia with a cutoff of 150 G/L. The dotted lines represent the following etiology-
unspecific cutoff levels: 0.5 (suggestive of fibrosis stage 2) and 1.0 (suggestive of fibrosis stage 3). BMI, body mass
index; Plt, platelets.
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Supplementary Figure 7. Predictors of significant liver fibrosis as assessed by HepaScore in homozygous carriers of the AAT
Pi*Z variant (Pi*ZZ). Four hundred and three Pi*ZZ carriers and 234 non-carriers (exploratory cohort) were subjected to clinical
evaluation and laboratory analysis. (A, B) Scatter plots of HepaScore values in women and men (A) and in non-obese (BMI <30
kg/m2) vs obese (BMI 30 kg/m2) individuals. (C) Scatter plot of HepaScore levels in Pi*ZZ carriers with serum GGT activities
within normal reference range vs those with serum GGT activities above the sex-specific ULN. (D) Scatter plot of HepaScore
values in Pi*ZZ carriers with and without thrombocytopenia with a cutoff of 150 G/L. The dotted lines represent the following
etiology-unspecific cutoff levels: 0.48 (suggestive of fibrosis stage 2) and 0.72 (suggestive of fibrosis stage 3). BMI, body
mass index; Plt, platelets.
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Age, y 58.4 ± 1.4 51.3 ± 2.0 53.3 ± 1.7 48.8 ± 4.2 54.6 ± 1.1
Women 40.8 50.0 46.7 41.2 44.4
BMI, kg/m2 25.5 ± 0.5 26.6 ± 0.7 26.7 ± 0.9 24.1 ± 0.9 25.8 ± 0.4
Diabetes mellitus 0 NA 0 5.9 NA
Mean alcohol consumption, g/d 9.5 ± 2.5 NA 9.1 ± 2.9 5.3 ± 1.9 NA
Liver fibrosis assessment
Liver stiffness, kPa 7.0 ± 0.8 6.5 ± 0.4 6.0 ± 0.4 6.8 ± 0.7 6.7 ± 0.4
Liver stiffness 7.1 kPa 22.5 27.1 33.3 41.2 27.2
Liver stiffness 10.0 kPa 12.7 16.7 6.7 11.8 13.2
APRI, units 0.46 ± 0.52 NA 0.38 ± 0.20 NA 0.45 ± 0.48
APRI 0.50 units 4.4 — 20 — 5.4
APRI 1.00 units 0 — 0 — 0
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%).
BMI, body mass index; NA, not available.














Age, y 54.8 ± 11.9 54.0 ± 13.8 58.4 ± 11.1 49.1 ± 16.5 48.6 ± 15.9
Women 47 43 57 34 39
BMI, kg/m2 25.0 ± 4.4 24.1 ± 4.3 23.6 ± 2.7 25.4 ± 5.7 23.5 ± 2.6
Diabetes mellitus 6 2 0 7 0
Mean alcohol consumption, g/d 6.3 ± 9.3 6.9 ± 12.7 12.4 ± 14.2 5.5 ± 11.1 4.1 ± 6.9
Liver fibrosis assessment
Liver stiffness, kPa 6.7 ± 6.3 5.9 ± 3.0 5.9 ± 3.6 8.2 ± 6.6 6.2 ± 4.1
Liver stiffness 7.1 kPa 23 23 15 39 6
Liver stiffness 10.0 kPa 14 8 8 24 6
APRI, units 0.39 ± 0.30 0.45 ± 0.55 0.28 ± 0.15 0.47 ± 0.44 0.40 ± 0.30
APRI 0.50 units 22.2 14.3 3.8 20.0 16.7
APRI 1.00 units 2.5 4.8 0 7.5 5.6
NOTE. As patients from the Netherlands and Belgium were assessed in Germany, they are included in the category
“Germany.” Quantitative measures are expressed as mean ± SD or as relative frequency (%). Patients from exploratory cohort
are shown.
BMI, body mass index.
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ALT, % of ULN 66.3 ± 30.3 79.9 ± 51.6 <.001 <.001
ALT ULN 12.0 19.1 .02 .002
ALT, U/L 28.4 ± 14.1 35.0 ± 25.1 <.001 <.001
AST, % of ULN 61.6 ± 19.4 74.4 ± 32.6 <.001 <.001
AST ULN 3.9 12.7 <.001 .001
AST, U/L 29.1 ± 8.6 32.0 ± 15.4 <.001 <.001
GGT, % of ULN 58.4 ± 47.4 99.7 ± 134.3 <.001 <.001
GGT ULN 11.6 23.7 <.001 <.001
GGT, U/L 30.6 ± 25.0 52.5 ± 78.0 <.001 <.001
ALP, % of ULN 60.0 ± 22.8 65.6 ± 22.9 .003 <.001
ALP ULN 4.0 8.6 .03 .002
ALP, U/L 68.6 ± 21.3 76.0 ± 24.3 <.001 .005
Bilirubin, % of ULN 46.9 ± 28.1 50.7 ± 28.6 .11 .80
Bilirubin ULN 7.7 5.7 .32 .18
Bilirubin, mmol/L 8.8 ± 5.3 9.5 ± 5.4 .11 .80
GLDH, % of ULN 58.5 ± 77.3 70.2 ± 73.4 .08 .02
GLDH ULN 7.7 16.2 .005 .05
GLDH, U/L 3.3 ± 3.9 5.0 ± 15.2 .12 .12
Platelets, G/L 258.7 ± 63.2 232.2 ± 67.2 <.001 .001
Platelets <150 G/L 1.8 8.8 .001 .012
INR, unitsa 0.96 ± 0.07 1.01 ± 0.09 <.001 <.001
Albumin, g/L 4.7 ± 0.5 4.4 ± 0.5 <.001 <.001
Lipid metabolism, mg/dL
Triglycerides 125.1 ± 70.4 101.8 ± 52.4 <.001 <.001
Cholesterol 216.4 ± 46.2 212.9 ± 44.7 .36 .47
LDL cholesterol 130.8 ± 41.4 122.4 ± 36.8 .03 .03
VLDL cholesterol 11.5 ± 4.2 9.6 ± 3.4 <.001 <.001
Further blood tests
Creatinine, mg/dL 0.93 ± 0.24 0.97 ± 0.65 .47 .40
Hemoglobin, mg/dL 14.4 ± 1.4 15.1 ± 1.4 <.001 <.001
White blood cell count, G/L 6.7 ± 2.1 7.2 ± 2.1 .007 .002
C-reactive protein, mg/dL 2.1 ± 3.9 2.8 ± 6.4 .08 .19
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%). Multivariable analyses were adjusted
for age, sex, BMI, presence of diabetes mellitus, and mean alcohol consumption.
ALP, alkaline phosphatase; GLDH, glutamate dehydrogenase; INR, international normalized ratio; LDL, low-density lipoprotein;
LLN, sex-specific lower limit of normal; ULN, sex-specific upper limit of normal; VLDL, very-low-density lipoprotein.
aOnly patients not taking anticoagulant medication were analyzed.
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Supplementary Table 4.Characteristics of Homozygous Carriers of the a1-Antitrypsin Pi*Z Variant (Pi*ZZ) Who Were
Recruited in Germany vs Those Who Were Recruited in Other European Countries
Variable
German Pi*ZZ
carriers (n ¼ 381)
Non-German Pi*ZZ




Age, y 55.6 ± 12.3 51.2 ± 14.4 <.001
Women 45.9 43.4 .57
BMI, kg/m2 25.0 ± 4.4 25.2 ± 4.6 .50
Mean alcohol consumption, g/d 5.6 ± 9.4 5.2 ± 9.9 .72
Risk factors
BMI 30 kg/m2 15.7 13.8 .55
Waist circumference, cm 95.1 ± 14.4 95.3 ± 11.7 .92
Diabetes mellitus 4.5 2.8 .44
Lung status
Cigarette consumption, pack-years 10.6 ± 12.6 11.2 ± 17.7 .72
CAT score, points 17.2 ± 8.2 14.2 ± 8.0 .03
LTOT 28.0 13.9 .003
Liver status
Liver stiffness, kPa 6.6 ± 6.0 6.9 ± 4.4 .60
Liver stiffness 7.1 kPa 22.3 29.5 .07
Liver stiffness 10.0 kPa 12.3 16.2 .22
CAP, dB/m 268 ± 58 262 ± 48 .37
CAP 248 dB/m 62.2 62.4 .98
CAP 280 dB/m 38.4 35.3 .60
APRI, units 0.41 ± 0.39 0.42 ± 0.36 .81
APRI 0.50 units 20.1 17.9 .62
APRI 1.00 units 4.1 5.7 .50
HepaScore, units 0.43 ± 0.32 0.41 ± 0.30 .85
HepaScore 0.48 units 36.4 33.3 .85
HepaScore 0.72 units 26.2 11.1 .31
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%). Patients from both exploratory and
confirmatory cohort were included.
BMI, body mass index.
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Supplementary Table 5.Characteristics of Pi*Z Non-Carriers and Homozygous Carriers of the a1-Antitrypsin Pi*Z Variant











Age, y 53.1 ± 14.6 49.1 ± 15.2 .03 —
Women 48.7 50.6 .71 —
BMI, kg/m2 25.1 ± 3.8 24.3 ± 3.8 .05 —
BMI 30 kg/m2 14.9 10.8 .27 —
Diabetes mellitus 5.6 3.9 .48 —
Mean alcohol consumption, g/d 7.9 ± 10.1 5.8 ± 10.4 0.06 —
AATD-related features
AAT serum level, mg/dL 139.7 ± 25.3 28.6 ± 16.6 <.001 <.001
CAT score, points 6.8 ± 6.0 14.2 ± 8.3 <.001 <.001
LTOT 0.4 11.3 <.001 <.001
Liver status
Liver stiffness, kPa 4.6 ± 1.7 7.0 ± 6.3 <.001 <.001
Liver stiffness 7.1 kPa 6.6 23.8 <.001 <.001
CAP, dB/m 246.2 ± 59.3 260.7 ± 54.9 .02 <.001
APRI, units 0.27 ± 0.12 0.42 ± 0.40 <.001 <.001
HepaScore, units 0.25 ± 0.21 0.41 ± 0.32 <.001 <.001
ALT, % of ULN 66.2 ± 30.1 76.6 ± 52. 8 .01 .001
AST, % of ULN 61.6 ± 19.4 76.2 ± 31.4 <.001 <.001
GGT, % of ULN 58.4 ± 47.4 58.4 ± 47.4 <.001 <.001
ALP, % of ULN 60.0 ± 22.8 98.9 ± 115.7 .004 <.001
Bilirubin, % of ULN 46.9 ± 28.1 56.2 ± 34.5 .003 .003
Platelets, G/L 258.7 ± 63.2 229.6 ± 71.4 <.001 <.001
INR, unitsa 0.96 ± 0.07 1.01 ± 0.10 <.001 <.001
Albumin, g/L 4.7 ± 0.5 4.5 ± 0.5 <.001 <.001
Lipid metabolism
Triglycerides, mg/dL 125.1 ± 70.4 100.1 ± 49.8 <.001 .002
VLDL cholesterol, mg/dL 11.5 ± 4.2 9.4 ± 3.3 <.001 .001
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%). Multivariable analyses were adjusted
for age, sex, BMI, presence of diabetes mellitus, and mean alcohol consumption.
BMI, body mass index; INR, international normalized ratio; LDL, low-density lipoprotein; LLN, sex-specific lower limit of
normal; ULN, sex-specific upper limit of normal; VLDL, very-low-density lipoprotein.
aOnly patients not taking anticoagulant medication were considered.
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(n ¼ 136) Overall <50 vs 50–59 <50 vs 60 50–59 vs 60
Characteristics
Age, y 38.5 ± 9.3 55.2 ± 3.1 67.1 ± 4.9 <.001 <.001 <.001 <.001
Women 43.5 44.8 47.8 .78 .84 .49 .61
BMI, kg/m2 24.7 ± 4.3 24.8 ± 4.4 24.7 ± 4.4 .90 .94 .69 .72
Mean alcohol, g/d 5.1 ± 7.9 7.6 ± 10.9 6.7 ± 11.3 .09 .05 .88 .08
AAT serum level,a mg/dL 25.7 ± 11.9 29.6 ± 22.5 31.6 ± 12.2 .01 .42 .002 .02
Risk factors
BMI 30 kg/m2 14.5 12.1 12.5 .82 .56 .64 .91
Diabetes mellitus 3.7 6.2 5.0 .70 .40 .65 .68
Relevant alcohol intakeb 8.1 13.8 8.8 .27 .16 .85 .21
Lung status
Smoking, pack-years 9.2 ± 13.1 12.6 ± 15.2 8.0 ± 12.8 .01 .07 .27 .01
CAT score, points 13.0 ± 8.1 17.2 ± 7.1 19.7 ± 6.9 <.001 <.001 <.001 .02
LTOT 11.6 23.5 41.3 <.001 .02 <.001 .002
AAT substitution 48.4 57.0 68.4 .01 .16 .001 .05
Liver status
Liver stiffness, kPa 5.9 ± 4.0 7.2 ± 7.2 6.9 ± 5.4 .11 .11 .04 .74
LSM 7.1 kPa 12.9 28.0 28.7 .004 .003 .002 .90
LSM 10.0 kPa 7.3 16.8 16.2 .05 .02 .03 .90
CAP, dB/m 258.0 ± 56.3 267.5 ± 58.1 273.0 ± 52.6 .11 .19 .04 .37
CAP  280 dB/m 33.7 37.4 44.3 .25 .55 .11 .27
APRI, units 0.34 ± 0.20 0.44 ± 0.48 0.43 ± 0.35 .02 .03 .02 82
HepaScore, units 0.30 ± 0.25 0.38 ± 0.32 0.58 ± 0.31 .006 .29 <.001 <.001
ALT, % of ULN 78.8 ± 56.4 84.6 ± 57.1 75.9 ± 39.4 .51 .22 .73 .49
AST, % of ULN 65.4 ± 26.6 79.0 ± 39.4 77.2 ± 28.4 <.001 <.001 <.001 .72
GGT, % of ULN 68.3 ± 40.9 109.7 ± 148.1 117.6 ± 166.6 .01 .01 .003 .58
ALP, % of ULN 58.9 ± 17.7 67.2 ± 25.3 70.0 ± 23.1 <.001 .004 <.001 .18
Bilirubin, % of ULN 52.6 ± 31.3 50.8 ± 30.0 53.2 ± 25.2 .37 .57 .47 .17
Platelets, G/L 234.4 ± 56.1 239.8 ± 70.9 222.1 ± 71.3 .08 .63 .10 .04
INR, unitsc 1.01 ± 0.09 1.02 ± 0.09 1.02 ± 0.10 .45 .52 .21 .52
Albumin, g/L 4.5 ± 0.5 4.5 ± 0.5 4.3 ± 0.5 <.001 .23 <.001 .003
Lipid metabolism, mg/dL
Triglycerides 93.7 ± 41.8 104.3 ± 57.6 106.5 ± 54.6 .15 .15 .07 .61
Cholesterol 197.5 ± 35.4 219.6 ± 38.9 219.8 ± 52.2 <.001 <.001 <.001 .48
LDL cholesterol 112.0 ± 32.6 128.7 ± 36.6 125.2 ± 38.7 <.001 <.001 .01 .20
VLDL cholesterol 9.2 ± 3.3 10.1 ± 3.5 9.4 ± 3.3 .45 .26 .88 .39
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%).
ALP, alkaline phosphatase; BMI, body mass index; INR, international normalized ratio; LDL, low-density lipoprotein; LLN, sex-
specific lower limit of normal; ULN, sex-specific upper limit of normal; VLDL, very-low-density lipoprotein.
aAAT serum levels of Pi*Z non-carriers and Pi*ZZ subjects, who did not receive AAT augmentation therapy, are shown. Mean
AAT serum level in all Pi*ZZ patients were 62.6 ± 53.0 mg/dL (<50 y) vs 72.4 ± 50.4 mg/dL (50–59 y) vs 81.9 ± 53.3 mg/dL
(60 y).
bAlcohol intake >12 g/d for women and >24 g/d for men (individuals with alcohol consumption >40 g/d for females or >60 g/
d for males had been excluded a priori).
cOnly patients not taking anticoagulant medication were considered.
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Age, y 54.8 ± 12.8 53.5 ± 13.2 .30 —
BMI, kg/m2 24.2 ± 5.1 25.2 ± 3.6 .01 —
Mean alcohol consumption, g/d 4.4 ± 7.4 8.4 ± 11.9 <.001 —
AAT serum level,a mg/dL 30.1 ± 17.2 27.2 ± 15.6 .27 .72
Comorbidities
BMI 30 kg/m2 10.5 15.0 .18 —
Diabetes mellitus 4.3 5.6 .56 —
Relevant alcohol intake,b % 11.0 9.9 .72 .06
Cigarette consumption, pack-years 8.4 ± 11.9 11.4 ± 15.3 .04 .14
CAT score, points 17.3 ± 7.9 16.6 ± 7.6 .40 .90
LTOT 25.5 26.4 .87 .40
Liver status
Liver stiffness, kPa 5.5 ± 3.5 7.8 ± 7.0 <.001 <.001
Liver stiffness 7.1 kPa 11.5 33.6 <.001 <.001
Liver stiffness 10.0 kPa 6.6 19.5 <.001 <.001
CAP, dB/m 254.2 ± 51.9 277.2 ± 58.8 <.001 .003
CAP 280 dB/m 29.9 46.1 .002 .02
APRI, units 0.30 ± 0.18 0.49 ± 0.45 <.001 <.001
HepaScore, units 0.30 ± 0.27 0.54 ± 0.32 <.001 <.001
ALT, % of ULN 72.2 ± 42.1 86.3 ± 57.6 .01 .02
ALT ULN 10.4 26.5 <.001 <.001
AST, % of ULN 76.3 ± 29.4 72.5 ± 35.2 .24 .22
AST ULN 12.6 12.8 .97 .77
GGT, % of ULN 80.8 ± 84.1 115.4 ± 163.3 .01 .02
GGT ULN 17.0 29.0 .01 .02
ALP, % of ULN 73.2 ± 24.2 59.3 ± 19.6 <.001 <.001
ALP ULN 14.0 4.2 .001 .002
Bilirubin, % of ULN 44.1 ± 22.7 58.9 ± 31.3 <.001 <.001
Bilirubin ULN 2.8 8.7 .01 .01
Platelets, G/L 253.1 ± 69.7 214.7 ± 59.7 <.001 <.001
INR, unitsc 0.99 ± 0.08 1.04 ± 0.09 <.001 <.001
Albumin, g/L 4.4 ± 0.5 4.5 ± 0.6 .37 .89
Lipid metabolism, mg/dL
Triglycerides 100.8 ± 54.5 102.6 ± 50.7 .75 .76
Cholesterol 224.7 ± 47.3 203.3 ± 38.8 <.001 <.001
LDL cholesterol 127.5 ± 37.6 118.1 ± 35.7 .02 .02
VLDL cholesterol 9.7 ± 3.2 9.6 ± 3.7 .93 .92
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%). Multivariable analyses were adjusted
for age, BMI, presence of diabetes mellitus, and mean alcohol consumption.
ALP, alkaline phosphatase; BMI, body mass index; INR, international normalized ratio; LDL, low-density lipoprotein; LLN, sex-
specific lower limit of normal; ULN, sex-specific upper limit of normal; VLDL, very-low-density lipoprotein.
aAAT serum levels of Pi*Z non-carriers and Pi*ZZ subjects, who did not receive AAT augmentation therapy are shown. Mean
AAT serum level in Pi*ZZ women was 70.2 ± 49.9 mg/dL and in Pi*ZZ men 74.4 ± 54.85 mg/dL.
bAlcohol intake >12 g/d for women and >24 g/d for men (individuals with alcohol consumption >40 g/d for females or >60 g/
d for males had been excluded a priori).
cOnly patients not taking anticoagulant medication were considered.
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Supplementary Table 8.Characteristics of Homozygous Carriers of the a1-Antitrypsin Pi*Z Variant (Pi*ZZ) With and Without a
Liver Stiffness Measurement Suggesting Significant Liver Fibrosis
Variable
Pi*ZZ, LSM <7.1 kPa
(n ¼ 308)





Age, y 52.9 ± 13.4 57.8 ± 11.3 .001
Women 52.6 22.1 <.001
BMI, kg/m2 24.2 ± 3.7 26.6 ± 5.7 <.001
Mean alcohol consumption, g/d 6.5 ± 10.0 7.0 ± 11.3 .71
AAT serum level,a mg/dL 30.9 ± 18.0 27.9 ± 16.1 .98
Comorbidities
BMI 30 kg/m2 8.8 26.9 <.001
Waist circumference, cm 93.3 ± 13.5 100.0 ± 15.7 .002
Diabetes mellitus 5.1 4.9 .97
Relevant alcohol intakeb 10.0 11.8 .65
Cigarette consumption, pack-years 9.8 ± 13.7 10.8 ± 14.9 .59
CAT score, points 16.7 ± 7.4 17.7 ± 8.8 .36
LTOT 25.5 26.4 .87
Liver status
Liver stiffness, kPa 4.8 ± 1.1 12.9 ± 9.4 <.001
CAP, dB/m 261 ± 54 288 ± 62 <.001
CAP 280 dB/m 33.9 55.0 .001
APRI, units 0.32 ± 0.15 0.68 ± 0.63 <.001
APRI 0.50 units 10.8 46.2 <.001
APRI 1.00 units 0.3 15.4 <.001
HepaScore, units 0.37 ± 0.29 0.63 ± 0.34 <.001
HepaScore 0.48 units 29.1 61.5 <.001
HepaScore 0.72 units 17.6 53.8 <.001
ALT, % of ULN 72.8 ± 40.9 103.0 ± 72.2 <.001
ALT ULN 13.3 37.9 <.001
ALT, U/L 31.0 ± 19.4 48.2 ± 35.0 <.001
AST, % of ULN 68.6 ± 24.5 92.8 ± 46.1 <.001
AST ULN 7.2 30.5 <.001
AST, U/L 28.5 ± 10.0 43.2 ± 22.8 <.001
GGT, % of ULN 73.1 ± 59.2 185.8 ± 236.3 <.001
GGT ULN 16.2 48.4 <.001
GGT, U/L 36.7 ± 33.5 103.7 ± 137.4 <.001
ALP, % of ULN 64.2 ± 20.9 70.3 ± 28.0 .03
ALP ULN 8.3 9.7 .67
ALP, U/L 73.2 ± 20.3 85.5 ± 33.1 <.001
Bilirubin, % of ULN 48.6 ± 28.8 57.7 ± 26.9 .01
Bilirubin ULN 5.2 7.1 .53
Bilirubin, mmol/L 9.1 ± 5.4 10.9 ± 5.1 .009
GLDH, % of ULN 59.0 ± 52.6 108.5 ± 112.1 <.001
GLDH ULN 9.3 39.7 <.001
GLDH, U/L 4.4 ± 16.8 7.0 ± 7.6 .23
Platelet count, G/L 244.1 ± 65.1 193.3 ± 58.9 <.001
Platelets <150 G/L 4.7 22.0 <.001
INR, unitsc 1.00 ± 0.08 1.07 ± 0.10 <.001
Albumin, g/L 4.5 ± 0.5 4.3 ± 0.5 .001
Lipid metabolism, mg/dL
Triglycerides 96.6 ± 44.2 117.5 ± 70.8 .001
Cholesterol 214.9 ± 44.9 207.4 ± 40.4 .15
LDL cholesterol 124.3 ± 37.0 116.6 ± 35.6 .09
VLDL cholesterol 9.7 ± 3.4 9.2 ± 3.6 .49
September 2019 Liver Disease in Pi*ZZ alpha-1 antitrypsin Deficiency 719.e16
Supplementary Table 9.Characteristics of Homozygous Carriers of the a1-Antitrypsin Pi*Z Variant (Pi*ZZ) With and Without











Age, y 53.6 ± 13.4 56.4 ± 11.9 .11
Women 52.2 16.2 <.001
BMI, kg/m2 24.5 ± 4.3 26.0 ± 4.6 .009
BMI 30 kg/m2 10.6 24.7 .001
Waist circumference, cm 93.8 ± 14.4 99.7 ± 13.3 .008
Diabetes mellitus 4.6 6.1 .63
CAT score, points 16.9 ± 7.7 17.4 ± 8.1 .61
LTOT 24.3 31.9 .19
Liver status
Liver stiffness, kPa 5.7 ± 3.0 11.0 ± 10.5 <.001
CAP, dB/m 262.1 ± 54.9 289.0 ± 61.1 .001
HepaScore, units 0.37 ± 0.29 0.66 ± 0.33 <.001
Biochemistry
ALT, % of ULN 67.5 ± 27.6 136.8 ± 84.4 <.001
AST, % of ULN 65.7 ± 17.2 112.9 ± 51.3 <.001
GGT, % of ULN 76.0 ± 60.9 207.0 ± 262.6 <.001
ALP, % of ULN 74.6 ± 20.3 81.7 ± 36.2 .53
Bilirubin, % of ULN 49.7 ± 29.1 55.8 ± 27.7 .11
GLDH, % of ULN 54.1 ± 37.4 131.0 ± 126.6 <.001
Platelet count, G/L 247.6 ± 61.3 165.8 ± 47.0 <.001
Triglycerides, mg/dL 97.2 ± 45.7 119.6 ± 71.8 .001
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%).
ALP, alkaline phosphatase; BMI, body mass index; GLDH, glutamate dehydrogenase; ULN, sex-specific upper limit of normal.
aOnly patients not taking anticoagulant medication were considered.
Supplementary Table 8.Continued
Variable
Pi*ZZ, LSM <7.1 kPa
(n ¼ 308)





Creatinine, mg/dL 0.97 ± 0.73 0.94 ± 0.27 .77
Hemoglobin, mg/dL 15.0 ± 1.4 15.4 ± 1.5 .08
White blood cell count, G/L 7.2 ± 2.0 7.1 ± 2.2 .70
C-reactive protein, mg/dL 2.9 ± 6.9 2.8 ± 3.9 .89
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%).
ALP, alkaline phosphatase; BMI, body mass index; GLDH, glutamate dehydrogenase; INR, international normalized ratio; LDL,
low-density lipoprotein; LLN, sex-specific lower limit of normal; ULN, sex-specific upper limit of normal; VLDL, very-low-
density lipoprotein.
aAAT serum levels of Pi*ZZ subjects without AAT augmentation therapy are shown. AAT serum levels in all Pi*ZZ subjects were
74.0 ± 54.3 mg/dL (LSM <7.1 kPa) vs 67.7 ± 47.0 mg/dL (LSM 7.1 kPa); P ¼ .33.
bAlcohol intake >12 g/d for women and >24 g/d for men (individuals with alcohol consumption >40 g/d for females or >60
g/d for males had been excluded a priori).
cOnly patients not taking anticoagulant medication were considered.
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Supplementary Table 10.Characteristics of Homozygous Carriers of the a1-Antitrypsin Pi*Z Variant (Pi*ZZ) With and Without











Age, y 52.0 ± 11.2 61.2 ± 11.4 <.001
Women 59.1 25.9 <.001
BMI, kg/m2 24.9 ± 4.3 25.1 ± 4.7 .66
BMI 30 kg/m2 14.1 17.6 .47
Waist circumference, cm 94.2 ± 12.3 97.8 ± 15.1 .07
Diabetes mellitus 5.4 7.1 .56
CAT score, points 16.2 ± 8.1 18.0 ± 7.4 .09
LTOT 26.8 34.1 .24
Liver status
Liver stiffness, kPa 5.5 ± 3.4 8.6 ± 8.6 <.001
CAP, dB/m 266.8 ± 55.0 277.6 ± 63.0 .19
APRI, units 0.21 ± 0.11 0.81 ± 0.17 <.001
Biochemistry
ALT, % of ULN 81.0 ± 50.1 89.6 ± 41.1 .18
AST, % of ULN 72.6 ± 27.1 83.2 ± 30.0 .006
GGT, % of ULN 75.0 ± 48.1 109.6 ± 115.8 .002
ALP, % of ULN 74.1 ± 20.9 83.0 ± 29.1 .01
Bilirubin, % of ULN 45.1 ± 20.8 53.4 ± 29.6 .01
GLDH, % of ULN 60.3 ± 65.0 80.7 ± 64.5 .02
Platelet count, G/L 247.3 ± 60.8 211.4 ± 64.0 <.001
Triglycerides, mg/dL 90.2 ± 36.0 112.1 ± 58.3 .001
NOTE. Quantitative measures are expressed as mean ± SD or as relative frequency (%).
ALP, alkaline phosphatase; BMI, body mass index; GLDH, glutamate dehydrogenase; ULN, sex-specific upper limit of normal.
aOnly patients not taking anticoagulant medication were considered.
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